Insulin-Like Growth Factor-I, Inflammatory Proteins, and Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
CONTEXT: Inflammation may have a pathogenic role in the progression of nonalcoholic fatty liver disease (NAFLD); by contrast, the role of anti-inflammatory molecules has not been addressed. Low circulating levels of the anti-inflammatory molecule IGF-I have been described in subjects with NAFLD. OBJECTIVE: The aim of the study was to elucidate the clinical significance of IGF-I in NAFLD and its relationship with inflammatory biomarkers and fibrosis. DESIGN AND SETTING: We conducted a cross-sectional study and in vitro experiments on hepatic HepG2 cells at the Internal Medicine and Gastrointestinal and Liver Units of the Universities of Catanzaro and Palermo. SUBJECTS: A total of 221 individuals with NAFLD diagnosed on ultrasonography (cohort 1) and 50 subjects with biopsy-proven NAFLD (cohort 2) participated in the study. INTERVENTION: Liver ultrasonography was performed on cohort 1, and hepatic biopsies were obtained from cohort 2. MAIN OUTCOME MEASURES: NAFLD fibrosis and Kleiner scores were calculated. IGF-I and inflammatory biomarker plasma concentrations were assessed with specific assays. In the in vitro study, real-time RT-PCR was used to assess the mRNA expression levels of acute-phase reactants. RESULTS: In the first cohort, circulating IGF-I levels showed an inverse correlation with NAFLD fibrosis score and inflammatory biomarkers; similarly in the second cohort, liver IGF-I mRNA levels and the fibrosis score showed a negative relationship. Finally, we showed that IGF-I was able to directly modulate the expression of acute-phase reactants, decreasing C-reactive protein and fibrinogen levels and up-regulating albumin expression in HepG2 cells. CONCLUSIONS: The present data suggest that evaluation of circulating IGF-I and proinflammatory markers might be useful to assess comprehensively the severity of the disease in individuals with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 5×
“Nevertheless, we consider our results important in attempting to understand the pathophysiological interaction between inflamJ Clin Endocrinol Metab, February 2013, 98(2):E304–E308 jcem.”
BackgroundMethodInfluentialInterleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytes
Castell, J. V., Gómez-Lechón, M. J., David, M., Andus, T., Geiger, T., Trullenque, R., Fabra, R., & Heinrich, P. C. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)80476-4 · Cited by 893
Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis
Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R., Zein, N. N., & Feldstein, A. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01774.x · Cited by 597
Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2060-x · Cited by 294
Arturi, F., Succurro, E., Procopio, C., Pedace, E., Mannino, G. C., Lugarà, M., Procopio, T., Andreozzi, F., Sciacqua, A., Hribal, M. L., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1227 · Cited by 103 · cited 2×
“It is, however, also possible to speculate that lowered IGF-I levels are a consequence of the presence of both NASH/advanced fibrosis and features of metabolic syndrome (abdominal obesity and insulin resistance), as indeed we have recently demonstrated that hepatic insulin resistance may affect IGF-I levels by modulat…”
BackgroundSelf-citation
Cited by
Insulin-Like Growth Factor (IGF) System in Liver Diseases
Adamek, A., & Kasprzak, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051308 · Cited by 284
“It has been shown that IGF1 has a direct an anti-inflammatory effect on hepatic cells [32].”
BackgroundInfluentialPetta, S., Ciminnisi, S., Di Marco, V., Cabibi, D., Cammà, C., Licata, A., Marchesini, G., & Craxì, A. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13889 · Cited by 215
Self-citationIGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner
Nishizawa, H., Iguchi, G., Fukuoka, H., Takahashi, M., Suda, K., Bando, H., Matsumoto, R., Yoshida, K., Odake, Y., Ogawa, W., et al. (2016) · Scientific Reports · doi:10.1038/srep34605 · Cited by 164
“In clinical settings, serum IGF-I levels are decreased in patients with NAFLD 11 and decreased levels of serum IGF-I are closely associated with the severity of fibrosis 12 .”
Yao, Y., Miao, X., Zhu, D., Li, D., Zhang, Y., Song, C., & Liu, K. (2019) · Endocrine · doi:10.1007/s12020-019-01982-1 · Cited by 43
Liang, S., Cheng, X., Hu, Y., Song, R., & Li, G. (2017) · Acta Paediatrica · doi:10.1111/apa.13685 · Cited by 32
“Secondly, hepatic insulin resistance could affect IGF-1 levels (2) and thirdly the increasing hepatic content of inflammatory cytokines can directly influence IGF-1 secretion from hepatocytes (12,13).”
Background
Metadata
- Authors
- Hribal, M. L., Procopio, T., Petta, S., Sciacqua, A., Grimaudo, S., Pipitone, R. M., Perticone, F., & Sesti, G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-02
- Volume
- 98
- Issue
- 2
- Pages
- E304-E308
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2100168771
- Cited by
- 88
- References
- 6
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.